Global Radiofrequency Ablation Devices Market- By Product (RF Generators, Disposable Equipment, and Reusable Equipment), By Application (Cardiology & Cardiac Rhythm Management, Surgical Oncology, Pain Management, Gynecology, and Other Applications), By End-User (Hospitals, Ambulatory Surgical Centers, and Other End-Users), By Region and Companies - Industry Segment Outlook, Market Assessment, Competition Scenario, Trends, and Forecast 2023-2032

Report Overview

Global Radiofrequency Ablation Devices Market size is expected to be worth around USD 12.5 Billion by 2032 from USD 4.3 Billion in 2022, growing at a CAGR of 11.6% during the forecast period from 2023 to 2032.

Radiofrequency ablation is a medical procedure in which heat produced by medium-frequency alternating current (350–500 kHz) is used to ablate a portion of the heart’s electrical conduction system, a tumor, or other damaged tissue. RFA is typically an outpatient procedure using local anesthetics or conscious sedation anesthesia.

When administered through a catheter, it is called radiofrequency catheter ablation. Radiofrequency current has two significant advantages over low-frequency AC or DC pulses that have been used in the past, it does not directly stimulate nerves or heart muscle, so it can often be used without general anesthesia, and it is very specific for treating the desired tissue without causing a lot of collateral damage.

*Actual Numbers Might Vary In The Final Report

Key Takeaways

• Market Growth: Radiofrequency ablation devices market has experienced steady expansion due to rising awareness about chronic pain conditions, cardiac arrhythmias and cancer as well as technological innovations in recent years.
• Cardiac Ablation: RFA devices are increasingly being utilized by cardiologists as an effective solution for atrial fibrillation and other arrhythmias that lead to atrial fibrillation, including atrial flutter. Ablation procedures help restore normal heart rhythm while simultaneously decreasing stroke risks.
• Cancer Treatment: Radio Frequency Abrasion devices are commonly utilized as interventional oncology treatments for specific tumors. RFA devices work by applying heat directly onto cancerous cells in liver, lung and kidney tumors – often successful tumor treatments!
• Device Components: RFA devices consist of several key elements; typically these are: radiofrequency generator, electrode and control interface. The generator creates radiofrequency energy which is delivered directly via electrode to the treatment site for application.
• Technological Advancements: Recent advances in RFA technology have resulted in more efficient procedures. Innovations to electrode design, navigation systems and energy delivery control systems have enhanced treatment outcomes and led to enhanced patient experiences.

Product Analysis

Disposable Equipment Has the Largest Market Share and Is Expected to Grow at The Fastest Rate During the Forecast Period

RF Generators, Disposable Equipment, and Reusable Equipment are the three segments that make up the market. During the forecast period, disposable equipment is anticipated to expand quickly and hold the largest market share of 38.7%. The advanced technology that can controllably create large areas of coagulative necrosis is relatively low in toxicity and has a lower risk of complications, driving the growth of the Radiofrequency Ablation Devices Market.

Over the forecast period, product launches will drive market expansion. Medtronic introduced the OsteoCool RF Ablation system in Canada to detect bone metastases. This one is the only dual-probe RF ablation system that offers flexible, individualized, and predictable treatment.

Application Analysis

Surgical Oncology dominates the market

Cardiology & Cardiac Rhythm Management, Surgical Oncology, Pain Management, Gynecology, and Other Applications comprise the market. Surgical oncology has dominated the market by 34% of the market share. Radiofrequency ablation can treat cancerous cells and increase the survival rate of high-risk patients with refractory and unresectable tumors.

Thus, the surgical oncology segment is gaining popularity. Patients with multiple tumors that cannot be treated with open surgery can benefit from RF ablation because it has fewer potential side effects, requires less time to recover, and is available.

End-User

The Hospital Category, Within the End User Segment, Accounted for the Largest Share

Due to the widespread use of RF ablation systems in hospitals, the Hospitals segment dominated the radiofrequency ablation devices market and will continue to do so during the forecast period. Because they provide the highest level of service, these healthcare facilities are the first choice for diagnosing and treating diseases.

Key Market Segments

Based on Product

• RF Generators
• Disposable Equipment
• Cannulas
• Needles
• Reusable Equipment
• Probes
• Electrodes

Based on Application

• Cardiology & Cardiac Rhythm Management
• Surgical Oncology
• Pain Management
• Gynecology
• Other Applications

Based on End-User

• Hospitals
• Ambulatory Surgical Centers
• Other End-Users

Drivers

A Rise in the Incidence of Chronic Diseases is a Driving Factor for the Market.

One of the primary factors driving the market’s overall expansion is the rising incidence of cardiovascular diseases and cancers (such as liver cancer, lung cancer, bone cancer, kidney cancer, hepatocellular carcinoma, bile duct cancer, pancreatic cancer, and others). The market is expanding significantly due to the steady growth in cardiac ablation and overall revenue.

The overall market’s expansion is also greatly aided by the rising demand for pain management (such as medication for arthritis and other chronic pain disorders) and the rising incidence of cardiovascular diseases and cancer. Throughout the time frame that was anticipated, the market is expanding steadily.

Additionally, senior individuals are more susceptible to chronic diseases, and one of the primary driving forces behind the market’s expansion is the worldwide aging population.

Restraints

Excessive Itching at the Injection Site and Other Factors May Hinder the Growth of the Market

The major factors that are severely obstructing the growth of the market include excessive itching at the injection site, damage to the surrounding blood vessels and nerve from hyperesthesia, damage to muscular tissue from needle insertions, damage to the structures that situated adjacent to the target nerve, and hyperesthesia.

Opportunities

Advantages in RFA of Cardiac Arrhythmia across the Globe Have Opened New Possibilities for Procedural Safety

New possibilities for procedural safety have emerged due to global RFA of cardiac arrhythmia advantages. The ability of RFA devices to treat arrhythmia with or without fluoroscopy has greatly improved with the development of EAM techniques and ICE imaging. As a result, its demand is anticipated to rise exponentially.

Trends

The Image-Guided Method is used to Apply Heat to Kill Cancer Cells.

The oncology market dominates the market for radiofrequency ablation devices. The worldwide rise in cancer cases exacerbates segmental growth. Radiofrequency ablation (RFA), a minimally invasive cancer treatment, uses an image-guided method to apply heat to kill cancer cells. A needle electrode is guided into a cancerous tumor by RFA using ultrasound, computed tomography (CT), or magnetic resonance imaging (MRI). High-frequency electrical currents are then passed through the electrode to ground pads placed on the body, resulting in focused heat that kills the cancer cells surrounding the electrode.

Additionally, it is suggested that microwave and radio frequency ablations are the most frequently utilized cancer therapy ablation techniques.

The availability of radiofrequency ablation devices for treating various types of cancer will also rise due to the growing investment in research and development, thereby accelerating the market’s growth.

Regional Analysis

North America Dominates the Global Radiofrequency Ablation Devices Market During the Forecast Period

Over the forecast period, North America is anticipated to continue to dominate at a revenue share of 37.4%. Technological advancements, a high purchasing power, a high cancer prevalence, and government support for high-quality healthcare are all major drivers of regional expansion. The American Cancer Society, Inc. estimates that 606,880 people will die from cancer, and 1,762,450 new cases will be diagnosed in the United States.

Asia-Pacific is expected to exhibit the fastest CAGR over the forecast period. The regional market is anticipated to benefit from the introduction of cutting-edge technology like multi-needle electrodes, which offer portability, accuracy, and cost-effectiveness at the same time. The Asia-Pacific region’s expansion is also fueled by rising disposable income, improved healthcare infrastructure, and rapidly expanding economic conditions in China and India’s emerging markets.

Key Regions

• North America
  • The US
  • Canada
  • Mexico
• Western Europe
  • Germany
  • France
  • The UK
  • Spain
  • Italy
  • Portugal
  • Ireland
  • Austria
  • Switzerland
  • Benelux
  • Nordic
  • Rest of Western Europe
• Eastern Europe
  • Russia
  • Poland
  • The Czech Republic
  • Greece
  • Rest of Eastern Europe
• APAC
  • China
  • Japan
  • South Korea
  • India
  • Australia & New Zealand
  • Indonesia
  • Malaysia
  • Philippines
  • Singapore
  • Thailand
  • Vietnam
  • Rest of APAC
• Latin America
  • Brazil
  • Colombia
  • Chile
  • Argentina
  • Costa Rica
  • Rest of Latin America
• Middle East & Africa
  • Algeria
  • Egypt
  • Israel
  • Kuwait
  • Nigeria
  • Saudi Arabia
  • South Africa
  • Turkey
  • United Arab Emirates
  • Rest of MEA

Key Players Analysis

Medtronic Plc announced its plan to acquire Epix Therapeutics Inc.

Major market players are concentrating on acquisitions to increase their market share and establish a global presence. For instance, the private medical device company Epix Therapeutics Inc., which develops catheter-based temperature-controlled cardiac ablation devices, was the target of Medtronic Plc as it announced its intention to acquire the company. The former expanded its portfolio of ablation devices due to this acquisition, and it now offers physicians advanced devices for treating cardiac arrhythmias.

Below are some of the most prominent global radiofrequency ablation device market players.

Market Key Players

• Avanos Medical Inc.
• Arthrex Inc.
• Sutter Medizintechnik GmbH
• AngioDynamics Inc.
• AtriCure Inc.
• Hologic Inc.
• Acessa Health Inc.
• EPIX Therapeutics Inc.
• Other Key Players.

Key Industry Developments

• In April 2022- The EnCompass Clamp was introduced by AtriCure as part of its Isolator Synergy ablation system. The platform, which features uniform pressure, parallel closure, and custom power utilizing synergy radiofrequency, will be utilized to ablate cardiac tissue during cardiac surgery to increase the efficiency of concurrent surgical ablations.
• In April 2022- The most recent version of Royal Philips’ KODEX-EPD system was released. It includes support for the Medtronic DiamondTemp ablation system and improved mapping and imaging capabilities for RF ablation, such as the brand-new Tissue Engagement Viewer.

Report Scope